Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak

BACKGROUND: The impact of some hasty medical decision made during the first wave of the Coronavirus Disease 2019 (COVID-19) remains unknown. We have evaluated the consequences of one of these precautionary measures: the withdrawal of the cyclin D-dependent kinases 4/6 inhibitor (CDK4/6i) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Sophie, Pflumio, Carole, Trensz, Philippe, Schaff-Wendling, Frederique, Weindling, Michal Kalish-, Fischbach, Cathie, Pierard, Laure, Limacher, Jean-Marc, Nader, Rita, Velten, Michel, Petit, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558751/
https://www.ncbi.nlm.nih.gov/pubmed/36414498
http://dx.doi.org/10.1016/j.clbc.2022.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558751/
https://www.ncbi.nlm.nih.gov/pubmed/36414498
http://dx.doi.org/10.1016/j.clbc.2022.10.006

Ejemplares similares